이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

PTSD 진단을 받은 전투 참전용사를 위한 디지털 바이오피드백

2026년 10월 1일 업데이트: NeuroBrave ltd.

PTSD 진단을 받은 전투 참전용사들을 대상으로 "멘탈 짐®" 바이오피드백 기반 중재의 효과 평가: 무작위 대조 시험

This randomized controlled trial (RCT) will evaluate the effectiveness of a digital biofeedback-based intervention ("Mental Gym®") designed to reduce Posttraumatic Stress Disorder (PTSD) symptoms and improve mental health. The intervention combines daily HRV biofeedback exercises using a wearable device (Garmin watch), a dedicated mobile application, and weekly group guidance sessions. A delayed-intervention control group design will be used. To account for expected attrition and ensure a final sample of 60 participants, approximately 80 subjects will be recruited. Physiological and self-report data will be collected pre- and post-intervention, weekly during the intervention, and at follow-ups (3 months post-intervention). The study population consists of combat veterans diagnosed with PTSD.

연구 개요

연구 유형

중재적

등록 (실제)

80

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Jerusalem, 이스라엘
        • NeuroBrave LTD - Remote Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • Sex: Male.
  • Age: 18 to 50 Years.
  • Diagnosis: Clinical diagnosis of Posttraumatic Stress Disorder (PTSD) with mild to moderate-severe symptom intensity.
  • Symptom Severity: A PCL-5 total score of up to 60 at screening.
  • Traumatic Event: PTSD diagnosis based on a traumatic event that occurred in the year 2000 or later.
  • Service Eligibility: Eligibility for Ministry of Defense (MOD) rehabilitation services.
  • Technical Proficiency: Ability to use a smartphone and a wearable device.

Exclusion Criteria:

  • High Symptom Severity: PTSD symptom severity exceeding the moderate-severe range (PCL-5 score > 60) or requiring more intensive clinical intervention.
  • Psychiatric Stability: Acute psychiatric instability, including active suicidal ideation or psychosis.
  • Medication: Current use of Olanzapine (Zyprexa) or Quetiapine (Seroquel).
  • Sleep Disturbances: Severe sleep impairment (score > 7 on the The Insomnia Severity Index).
  • Functional Impairment: Severe impairment in concentration or cognitive processing that precludes the use of digital biofeedback tools.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: 멘탈 짐® 즉각 개입

The intervention is an 8-week hybrid program designed to reduce symptoms of PTSD and improve mental health. The program includes weekly online sessions (via Zoom) with a specialist psychologist experienced in biofeedback and trauma therapy. These sessions guide participants through the program, provide education on trauma and autonomic system and explain the biofeedback exercises. In addition to the weekly group sessions, participants engage in a dailyself-practice delivered through the NeuroBrave Sense mobile application, utilizing the provided wearable device ( Garmin watch) for real time biofeedback practices. Supplementary mental practice assignments are also delivered to participants via WhatsApp.

간섭 없음: Delayed Intervention (Waitlist Control plus Garmin Watch)

Participants in this arm will initially serve as a no-intervention control group for a period of 8 weeks, during which they will continue with their Treatment as Usual (TAU). Following this 8-week period, they will receive the full 'Mental Gym®' intervention, identical to the experimental group, including the mobile application, and weekly sessions.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in PTSD Symptom Severity (PCL-5 Total Score)
기간: Baseline (Week 0) and Post-Intervention (Week 8).

The primary outcome is the change in the total score of the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5). The PCL-5 is a 20-item self-report measure; items are rated on a 0-4 point scale. Total score ranges from 0 to 80, where higher scores indicate greater symptom severity. PCL scores are expected to reduce in the intervention but not in the control groups.

Baseline (Week 0) and Post-Intervention (Week 8).

2차 결과 측정

결과 측정
측정값 설명
기간
Long term retention of Treatment Effects in the Intervention Group
기간: Baseline (Week 0), Post-Intervention (Week 8), 1.5-month Follow-up (Week 14), and 3-month Follow-up (Week 20)

To assess long term improvement trajectories and retention, we will combine all intervention arm participants and conduct longitudinal within subjects analysis on primary and secondary change measures at post intervention, as well as 1.5-month Follow-up (Week 14), and 3-month Follow-up (Week 20). This analysis will also be used to identify subpopulations within our sample for whom the treatment was more or less beneficial.

We expect the clinical improvement to remain significant through the follow up time points.

Baseline (Week 0), Post-Intervention (Week 8), 1.5-month Follow-up (Week 14), and 3-month Follow-up (Week 20)
Change in Autonomic Regulation (Resting HRV)
기간: Baseline (Week 0) and Post-Intervention (Week 8)

change in resting heart rate variability (HRV) will be used as a physiological marker of autonomic regulation. HRV will be derived from inter-beat interval data collected during 5 min resting conditions during the first and the last group sessions using a wearable device and summarised using standard time-domain metrics (e.g., RMSSD). Higher HRV values and lower heart rate (HR) reflect greater parasympathetic activity and improved autonomic regulation. Resting HRV scores are expected to increase and resting HR to decrease in the intervention but not in the control groups.

Baseline (Week 0) and Post-Intervention (Week 8)
Change in Generalized Anxiety Symptoms (GAD-7)
기간: Baseline (Week 0) and Post-Intervention (Week 8)

Generalized anxiety symptoms will be assessed using the Generalized Anxiety Disorder 7-item questionnaire (GAD-7), a validated self-report measure of anxiety severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptoms. Generalized anxiety symptoms are expected to reduce in the intervention but not in the control groups.

Baseline (Week 0) and Post-Intervention (Week 8)
Change in Depressive Symptoms (PHQ-9)
기간: Baseline (Week 0), Post-Intervention (Week 8)

Depressive symptoms will be measured using the Patient Health Questionnaire-9 (PHQ-9), a validated self-report instrument assessing the severity of depressive symptoms over the past two weeks. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Depressive symptoms are expected to reduce in the intervention but not in the control groups

Baseline (Week 0), Post-Intervention (Week 8)
Change in Psychological Resilience (CD-RISC-10)
기간: Baseline (Week 0), Post-Intervention (Week 8)

Psychological resilience will be assessed using the 10-item Connor-Davidson Resilience Scale (CD-RISC-10), a validated self-report measure of perceived resilience and stress coping capacity. Total scores range from 0 to 40, with higher scores indicating greater resilience.Psychological resilience is expected to reduce in the intervention but not in the control groups.

Baseline (Week 0), Post-Intervention (Week 8)
Change in Sleep Quality (ISI)
기간: Baseline (Week 0), Post-Intervention (Week 8)

Sleep quality will be measured using the Insomnia Severity Index (ISI), a validated self-report questionnaire assessing subjective sleep quality. The total SQS score will be used, with higher scores indicating poorer sleep quality. Sleep quality is expected to reduce in the intervention but not in the control groups.

Baseline (Week 0), Post-Intervention (Week 8)

기타 결과 측정

결과 측정
측정값 설명
기간
Weekly Change in PTSD Symptom Severity (PCL-6)
기간: Baseline, and weekly through Week 8

The PTSD Checklist - 6-item version (PCL-6) is a validated self-report screening tool for Post-Traumatic Stress Disorder. It assesses symptoms such as intrusive thoughts, avoidance, and hyperarousal. Total scores range from 6 to 30, with higher scores indicate greater symptom severity. A decrease in scores over time represents clinical improvement.

Baseline, and weekly through Week 8
Weekly Change in Psychological Wellbeing (ORS)
기간: Baseline, and weekly through Week 8

The Outcome Rating Scale (ORS) is a 4-item visual analogue scale designed to measure change in three areas of client functioning: individual (personal well-being), interpersonal (family/close relationships), and social (work/school/friendships), as well as overall well-being. Total scores range from 0 to 40, with higher scores indicate better psychological wellbeing and functioning. An increase in scores over time represents improvement.

Baseline, and weekly through Week 8

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 9월 15일

기본 완료 (실제)

2026년 9월 14일

연구 완료 (실제)

2026년 9월 14일

연구 등록 날짜

최초 제출

2026년 3월 5일

QC 기준을 충족하는 최초 제출

2026년 3월 5일

처음 게시됨 (실제)

2026년 3월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • P_2025176

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다